Aerie Pharmaceuticals

Aerie Pharmaceuticals is a biotechnology company that engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of ophthalmic diseases. The company was founded in 2005 and is headquartered in Bridgewater, New Jersey with research facilities in Research Triangle Park, North Carolina. Aerie Pharmaceuticals, Inc. is a former subsidiary of Duke University Medical Center.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

After Golden Cross, Aerie Pharmaceuticals (AERI)'s Technical Outlook is Bright

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced that the compensation committee of Aerie Pharmaceutical's board of directors granted one new employee an award totaling 16,900 stock options that will vest over 4 years, with 25% vest

Aerie Pharmaceuticals Announces New Employee Inducement Grant

The consensus price target hints at a 75.1% upside potential for Aerie (AERI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 75% Upside in Aerie (AERI): Can the Stock Really Move This High?

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Hans Vitzthum – Investor Relations Raj Kannan – Chief Executive Officer Peter Lang – Chief Financial Officer Gary Sternberg – Chief Medical Officer Michelle Senchyna – Head-Clinical Development and Operations Casey Kopczynski – Co-Founder, Head-Research and External Innovation Conference Call Participants Serge Belanger – Needham Annabel Samimy – Stifel Stacy Ku – Cowen Greg Fraser – Truist Operator Good afternoon. Thank you for standing by, and welcome to the Aerie Pharmaceuticals Second Quarter 2022 Earnings Conference Call.

Aerie Pharmaceuticals, Inc.'s (AERI) CEO Raj Kannan on Q2 2022 Results - Earnings Call Transcript

Aerie (AERI) Q2 loss narrows year over year and revenues beat estimates in the second quarter of 2022.

Aerie (AERI) Q2 Loss Narrower Than Expected, Sales Beat

Aerie (AERI) delivered earnings and revenue surprises of 38.46% and 2.59%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Aerie Pharmaceuticals (AERI) Reports Q2 Loss, Tops Revenue Estimates

DURHAM, N.C.DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today reports financial results for the second quarter ended June 30, 2022 and provides its business and pipeline objectives and financial guidance for 2022 and beyond, including its expectation to achieve cash flow break even during 2024. “Aerie delivered a strong second quarter perfo

Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today announced that the first participant has been dosed in the Phase 3 registrational “COMET-3” study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED). COMET-3 is the second of three trials in the Phase 3 registrational program for AR-15

Aerie Pharmaceuticals Announces First Participant Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Disease

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present second quarter 2022 financial results after the market closes Thursday, August 4, 2022. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss Aerie's financial results and provide a general business update

Aerie Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022 at 5:00 p.m. ET

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Raj Kannan, Chief Executive Officer, along with Peter Lang, Chief Financial Officer, and Dr. Gary Sternberg, Chief Medical Officer, will present at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. Eastern Time in New York City, NY. Date:   June 10, 202

Aerie Pharmaceuticals to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET

Aerie Pharmaceutials (AERI) doses the first patient in a phase III study on its investigational TRMP8 agonist drug for the treatment of dry eye disease.

Aerie (AERI) Starts Late-Stage Study to Treat Dry Eye Disease

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) has dosed the first patient in the Phase 3 COMET-2 study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED). This study is the first of three trials in the Phase 3 registrational program for AR-15512.

Aerie Pharmaceuticals Begins Patient Dosing In Late-Stage Dry Eye Disease Study

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today announced that the first participant has been dosed in the Phase 3 registrational “COMET-2” study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED). COMET-2 is the first of three trials in the Phase 3 registrational program for AR-155

Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Hans Vitzthum – LifeSci Partners Raj Kannan – Chief Executive Officer Gary Sternberg – Chief Medical Officer Peter Lang – Chief Financial Officer Conference Call Participants Louise Chen – Cantor Serge Belanger – Needham & Company Annabel Samimy – Stifel Stacy Ku – Cowen and Company François Brisebois – Oppenheimer Carly Kenselaar – Citigroup Oren Livnat – H.C. Wainwright Operator Good afternoon.

Aerie Pharmaceuticals' (AERI) CEO Raj Kannan on Q1 2022 Results - Earnings Call Transcript

Aerie (AERI) misses on both earnings and revenues for the first quarter of 2022.

Aerie (AERI) Q1 Loss Wider Than Expected, Revenues Rise Y/Y

Aerie (AERI) delivered earnings and revenue surprises of -1.54% and 1.17%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Aerie Pharmaceuticals (AERI) Reports Q1 Loss, Misses Revenue Estimates

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today reports financial results for the first quarter ended March 31, 2022 and reaffirms the business and pipeline objectives and financial guidance previously reported for 2022. “We continue to execute well on our three strategic pillars to build out Aerie version 2.0. I am pleased to report stron

Aerie Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present first quarter 2022 financial results after the market closes Thursday, May 5, 2022. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss Aerie's financial results and provide a general business update. De

Aerie Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on Thursday, May 5, 2022 at 5:00 p.m. ET

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that fourteen abstracts related to Aerie's Rhopressa®/netarsudil, AR-15512 in dry eye and “ROCK'Sters” anti-inflammatory programs will be presented at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2022) in Denver, Colorado, May 1 through 4, 2022. Gary

Aerie Pharmaceuticals Announces Presentations at the Association for Research in Vision and Ophthalmology Annual Meeting in Denver, Colorado, May 1-4, 2022

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that three abstracts will be presented at the American Society of Cataract and Refractive Surgery (ASCRS 2022) in Washington, D.C., on April 22 through 26, 2022. Gary Sternberg, M.D., Chief Medical Officer at Aerie commented, "Aerie is pleased to have multiple scientific presentatio

Aerie Pharmaceuticals Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2022) in Washington, D.C., April 22-26, 2022

Aerie (AERI) is progressing well with the development of its ophthalmology pipeline. Its partnership with Santen Pharmaceuticals allows it to expand the presence of its drugs outside the United States.

Aerie (AERI) Expands Market Presence Despite Stiff Competition

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Raj Kannan, Chief Executive Officer, along with Peter Lang, Chief Financial Officer, and Dr. Gary Sternberg, Chief Medical Officer, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 3:00 p.m. Eastern Time.

Aerie Pharmaceuticals to Participate in the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 3:00 p.m. ET

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals Appoints Peter Lang as Chief Financial Officer

Aerie Pharmaceuticals Appoints Peter Lang as Chief Financial Officer

The Aerie Pharmaceuticals Inc (NASDAQ: AERI) stock increased by 29.49% in the most recent trading session. This is why.

Aerie Pharmaceuticals (AERI) Stock: Why It Substantially Increased

Aerie (AERI) beats earnings and sales estimates for the fourth quarter of 2021. AERI's shares increase in the after-market trading session following the news.

News for Aerie Pharmaceuticals Stock (AERI)